Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials Toshinori Murata (Japan)
Faricimab in Neovascular Age-Related Macular Degeneration: Efficacy, Safety, and Durability Through Week 48 in TENAYA and LUCERNE Robyn Guymer (Australia)
Incidence of New-onset Exudative AMD in Patients Treated with Pegcetacoplan for Geographic Atrophy in OAKS and DERBY TBA
Faricimab for Macular Edema Due to Retinal Vein Occlusion: Rationale and Design of the Phase 3 BALATON and COMINO Trials Hemal Mehta (Australia)
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials TBA
Predicting lesion shrinkage in eyes with myopic choroidal neovascularization from features on OCT angiography Jing Liu (People's Republic of China)
